Novel Immunotherapies for Psoriasis: Clinical Research Delivers New Hope for Patients and Scientific Advances

Journal of Investigative Dermatology Symposium Proceedings

Volumn 9, Issue 1, 2004, Pages 79-83

  Gottlieb, Alice B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Immunobiologics; Psoriasis; T cell activation

Indexed keywords

CYTOKINE; ETANERCEPT; IMMUNOLOGIC AGENT; INFLIXIMAB;

CLINICAL TRIAL; CONFERENCE PAPER; GENE TARGETING; HUMAN; IMMUNOBIOLOGY; IMMUNOTHERAPY; INFLAMMATION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSORIASIS; SIDE EFFECT; SKIN MANIFESTATION; T LYMPHOCYTE;

EID: 0346671342     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1087-0024.2004.00831.x     Document Type: Conference Paper

References (73)

1. Abrams J, Kelley S, Hayes E, et al: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192:681-94, 2000
2. Asadullah K, Sterry W, Stephanek K, et al: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 Therapy: A new therapeutic approach. J Clin Invest 101:783-794, 1998
3. Bos JD, VanJoost T, Powles AV, et al: Use of cyclosporin in psoriasis. Lancet 23: 1500-1505, 1989
4. Botros N, Pickover L, Das KM: Image of the month. Gastroenterol 118:654, 2000
5. Braughman RPI, Lower EE: Inflximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18:70-74, 2001
6. Braun J, Brandt J, Listing J, et al: Treatment of active ankylosing spondylitis with inflximimab: A randomised controlled multicentre trial. Lancet 359:1187-1193, 2002
7. Cambell S, Ghosh S: Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 13:191-192, 2001
8. Chaudhari U, Romano P, Mulcahy LD, et al: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 357:1842-1847, 2001
9. Couriel DR, Hicks K, Giralt S, et al: Role of tumor necrosis factor-alpha inhibition with inflximab in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 12:582-587, 2000
10. De Clercq E: Perspectives for the chemotherapy of AIDS. Anticancer Res 7:1023-1038, 1987
11. daSilva AJ, Brickelmaier M, Majeau GR, et al: Alefacept, an immunomodulatory recombinant LFA-3/lgG1 fusion protein, induces CD16 signaling and CD2/ CD16-dependent apoptosis of CD2+ cells. J Immunol 168:4462-4471, 2002
12. De Boer O, Wakelkamp I, Pals S, et al: Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch Dermatol Res 286:304-11, 1994
13. Ellis CN, Fradin MS, Messana JM, et al: Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324:277-284, 1991
14. Ellis CN, Krueger GG, Group ACS: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248-255, 2001
15. Ettehadi P, Greaves MW, Wallach D, et al: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96:146-151, 1994
16. Fabrizio C, Niccoli L, Salvarani C, et al: Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases. Arthr Rheum 44:2933-2935, 2001
17. Frederiksson T, Pettersson U: Severe psoriasis oral therapy with a new retinoid. Dermatologica 157:238-244, 1978
18. Friedrich MKS, Henze M, Docke WD, Sterry W, Asadullah K: Flow cytometric characterization of lesional T cells in psoriasis: Intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Derm Res 292:59-521, 2000
19. Gilhar A, David M, Ullmann Y, et al: T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. 109:283-288, 1997
20. Gordon KB, Krueger JG, Gilleaudeau P, Kikuchi T, et al: Psoriasis-related subpopulations of memory CD4+ and CD8+ T cells are selectively reduced by Alefacept. J Invest Dermatol in press, 2002
21. Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spcndylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346:1349-1356, 2002
22. Gottlieb AB: New immunomodulatory drugs. Ann Dermatol Venereol 129:S165, 2002a
23. Gottlieb AB: Clinical research helps elucidate the role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of T1 mediated immune disorders: Use of targeted immunotherapeutics as pathogenic probes. Lupus 12:190-194, 2003
24. Gottlieb AB, Grossman RM, Khandke L, et al: Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 98:302-309, 1992
25. Gottlieb AB, Krueger JG: New therapies for psoriasis: Use of targeted immunotherapies as treament and as immunopathogenic probes. Dermatologic Clinics in press, 2002
26. Gottlieb A, Krueger JG, Bright R, et al: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Amer Acad Dermatol 42:428-435, 2000
27. Gottlieb AB, Miller B, Lowe N, et al: Subcutaneously administered efalizumab (antiCD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cut Med Surg 7:198-207, 2003
28. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M: Psoriasis as a model for T cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a monoclonal antibody. Arch Derm 138:591-600, 2002a
29. Gottlieb AB, Lebwohl M, Tortoritus MC, et al: Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Amer Acad Dermatol 47:692-700, 2002b
30. Gottlieb AB, Masud S, Ramamurthi R, et al: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor monoclonal antibody (Infliximab) treatment of moderate to severe psoriasis vulgaris. J Amer Acad Dermatol 48: 68-75, 2003
31. Gottlieb AB, Matheson RT, Lowe NJ, Zitnik RJ: Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol 119:234, 2002c
32. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG: Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. JAAD 829-835, 2003
33. Gottlieb SL, Gilleaudeau P, Johnson R, et al: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Medicine 1:442-447, 1995
34. June CH, Ledbetter JA, Linsley PS, et al: Role of the CD28 receptor in T cell activation. Immunol Today 11:211-216, 1990
35. Kakurai M, Fujita N, Murata S, et al: Vasoactive intestinal peptide regulated its receptor expression and functions of human keratinocytes via type I vasoactive intestinal peptide receptors. J Invest Dermatol 116:743-749, 2001
36. Khandke L, Ashinoff R, Krane JF, et al: Cycloporine in psoriasis treatment: Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor-alpha/epidermal growth factor receptor pathways. Arch Dermatol 127:1172-1179, 1991
37. Kimber I, Cumberbatch M, Dearman RJ, et al: Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol 142:401-412, 2000
38. Langley RD, Christophers E, Lebwohl M: Efficacy and safety of multiple courses of intramuscular alefacept in patients with chronic plaque psoriasis. J Invest Dermatol in press, 2002
39. Leonardi C, Tyring S, Gottlieb AB, Walicke P, Dummer W, Papp K: Efalizumab (anti-CD11a) is safe and effective in the treatment of psoriasis: Results of the 12 week first treatment period from 2 phase III trials. J Invest Dermatol 119:242, 2002
40. Lowe N, Griffiths C, Gottlieb AB: Selective reductions in memory-effector (CD45RO+) T cells by alefacept are related to clinical improvement in psoriasis. J Invest Dermatol 119:345, 2002
41. Magilavy D: Immunopharmacologic effects of Amevive (LFA3TIP) in chronic plaque psoriasis: selectivity for peripheral memory-effector (CD45RO+) over naive (CD45RA+) T cells: AMEVIVE Clinical Study Group. Br J Dermatol 141:990, 1999
42. Maini R, St. Clair EW, Breedveld F, et al: Infliximab (chimeric anti-tumour necrosis factor-alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932-1939, 1999
43. Martinez F, Nos P, Benlloch S, et al: Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 7:323-326, 2001
44. Mease PJ, Goffe BS, Metz J, et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385-390, 2000
45. Mease P, Kivitz A, Burch F, et al: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial. Arthr Rheum 44:S90, 2001
46. Morhenn VB: Langerhans cells may trigger the psoriatic disease process via production of nitric oxide. Immunol Today 18:433-436, 1997
47. Nestle F, Nickoloff B: Dermal dendritic cells are important members of the skin immune system. Adv Exp Med Biol 378:111-6, 1995
48. Nickoloff BJ, Griffiths CEM: T lymphocytes and monocytes bind to keratinocytes in frozen sections of biopsy specimens of normal skin treated with gamma interferon. J Amer Acad Dermatol 20:736-743, 1989
49. Nickoloff BJ, Kunkel SL, Burdick M, et al: Severe combined immunodeficiency mouse and human psoriatic skin chimeras: validation of a new animal model. Amer J Pathol 146:580-588, 1995
50. Norris DA: Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J Invest Dermatol 95:111S-120S, 1990
51. Oh CJ, Das KM, Gottlieb AB: Treatment with anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Amer Acad Dermatol 42:829-830, 2000
52. Onuma S: Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J Dermatol 21:223-32, 1994
53. O'Shea JJ, Lipsky P: Cytokines and autoimmunity. Nature Rev/Immunol 2:37-45, 2002
54. Papp KBR, Bissinette R, Krueger JG, et al: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45:665-674, 2001
55. Present DH, Rutgeerts P, Targan S, et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405, 1999
56. Scallon BJ, Moore MA, Trinh H, et al: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251-259, 1995
57. Schothorst AA, Evers LM, Noz KC, et al: Pyrimidine dimer induction and repair in cultured human skin keratinocytes or melanocytes after irradiation with monochromatic ultraviolet radiation. J Invest Dermatol 96:916-920, 1991
58. Schuler G, Steinman RM: Murine epidermal Langerhans cells mature into potent immunostimulatory dentritic cells in vitro. J Exp Med 161:526-546, 1985
59. Skobe M, Detmar M: Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc 5:14-19, 2000
60. Smith JR, Levinson RD, Holland GN, et al: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45:252-2557, 2001
61. Springer TA, Dustin ML, Kashimoto TK, et al: The lymphocyte function-associated LFA-1, CD2, and LFA-2 molecules: cell adhesion receptors of the immune system. Ann Rev Immunol 5:223-252, 1987
62. Springer TA: Adhesion receptors of the immune system. Nature 346:425-434, 1990
63. Steinfeld S, Demols P, Salmon I, Kiss R, Appelboom T: Infliximab in pateints with primary Sjogren's syndrome: A pilot study. Arthr Rheum 44:2371-2375, 2001
64. Tan JH, Gordon M, Lebwohl O, et al: Improvement of pyoderma gangrenosurn and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137:930-933, 2001
65. Targan SR, Hanauer SB, VanDeventer SJH, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. N Engl J Med 337:1029-1035, 1997
66. tenHove T, vanMontfrans C, Peppelenbosch MP, vanDeventer SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50:206-211, 2002
67. Thomas P: IL-4-induced immune deviation as therapy of psoriasis. Arch. Derm Res 293:30, 2001
68. Trepicchio W, Ozawa M, Walters IB, et al: IL-11 is an immune-modulatory cytokine which downregulates IL-12, Type 1 cytokines, and multiple inflammation-associated genes in patients with psoriasis. J Invest Dermatol 112:598, 1999
69. van Noesel C, Miedema F, Brouwer M, et al: Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature 333:850-852, 1988
70. VanOosten BW, Barkhof F, Truyen L, et al: Increased MRI activity and immune activation in two multiple sclerosis patients treated with monoclonal anti-tumor necrosis factor antibody CA2. Neurology 47:1531-1534, 1996
71. Wang Y, Jensen PJ: Regulation of the level and glycosylation state of plasminogen activator inhibitor type 2 during human keratinocyte differentiation. Differentiation 63:93-99, 1998
72. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887, 1996
73. Xia AY, Li B, Detmar M, Yancopoulos GD, Rudge JS: Chronic transgenic delivery of VEGF to the skin leads to the development of a psoriasis-like phenotype. J Invest Dermatol in press, 2002